CSPC Pharmaceutical Group Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CVG.F | 002422.SZ | 300181.SZ | CUP.F | D4S.F | 0570.HK | |
|---|---|---|---|---|---|---|
| Market cap | 10.81B | 71.95B | 8.83B | 65.86B | 31.06B | 6.19B |
| P/E (TTM) | 11.8 | 36.5 | 14.1 | 23.7 | 20.8 | — |
| Forward P/E | — | 30.2 | 13.1 | 0.3 | 46.1 | 8.1 |
| Price/book | 2.2 | 2.8 | 2.8 | 5.6 | 3.1 | 0.3 |
| Dividend yield | 4.75% | 1.37% | 5.57% | 1.93% | 3.57% | — |
| 1-year change | +6.12% | +28.94% | −26.75% | −1.48% | −17.91% | −48.04% |
| Today | +3.60% | +4.02% | +0.16% | +4.33% | +5.64% | +2.93% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All CVG.F news ›CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For SYS6062 In China
CSPC Pharmaceutical Group Limited announced that SYS6062 developed by the Group has obtained approval from the National Medical Products Administration of the People?s Republic of China to conduct... CSPC Pharmaceutical Group Limited…
CSPC Pharmaceutical Group Limited: Total Return chart (Dividends reinvested) - Hong Kong S.E. stock market
See the history of CSPC Pharmaceutical Group Limited, with dividends reinvested. (Total Return chart) 1093 Stock market Total Return chart CSPC Pharmaceutical Group Limited Past dividends on CSPC Pharmaceutical Group Limited All financial…
CSPC Pharmaceutical Group Limited: Relative Strength Chart - Stock Hong Kong S.E.
Compare CSPC Pharmaceutical Group Limited with the company of your choice via a Relative Strength chart. Real-time 1093 price, Hong Kong S.E. stock exchange Relative Strength Chart CSPC Pharmaceutical Group Limited All financial news and…
CSPC Pharmaceutical Says Phase I Clinical Trial Of SYH2083 Eye Drops Initiated In China
TradingView CSPC Pharmaceutical Says Phase I Clinical Trial Of SYH2083 Eye Drops Initiated In China
CSPC Pharmaceutical Group Limited Presents Data From Phase I Clinical Study Of SYS6002 As Monotherapy For The Treatment Of Advanced Cervical Cancer At IGCS2026
CSPC Pharmaceutical Group Limited presented the data from the Phase I clinical study of SYS6002 as monotherapy for the treatment of advanced cervical cancer as a rapid oral presentation at the 2026...
CSPC Pharmaceutical Group Limited Presents Results of Phase III Clinical Study of Efmedaglutide Alfa Injection in Combination with Metformin in Chinese Adult Patients with Type 2 Diabetes Mellitus
CSPC Pharmaceutical Group Limited announced that the Group has presented the positive results of the Phase III clinical study of the glucagon-like peptide-1 receptor agonist Efmedaglutide Alfa...
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com3
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.